16th Winter Conference
on Medicinal & Bioorganic Chemistry

January 29th - February 2nd 2023

Steamboat Springs Resort, Colorado

Agenda

Sunday, January 29th 2023

Drug Hunting

Program Chair: Klemens Hoegenauer, Novartis

Kentaro Futatsugi Pfizer

Discovery of DGAT2 Inhibitors for the Treatment of NASH

Woody Sherman Psivant Therapeutics

Is it Time for Computation-driven Drug Design? The Discovery of a Small Molecule STING Agonist using the QUAISAR Computational Platform

Jason Shields AstraZeneca

Medicinal Chemistry with the Fifth Element: Discovery of Arginase Inhibitor AZD0011

Ian M. Bell Merck

Drug Hunter Award:

CGRP Receptor Antagonists for the Treatment of Migraine

Networking Session

Welcome Reception

Monday, January 30th 2023

Enabling Methodology and Technology

Program Chair: Iulia Strambeanu, Janssen

David Leitch University of Victoria

Mapping Chemical Space via High-throughput Experimentation: New Tools, New Reactions, and New Bicyclic Scaffolds

Song Lin Cornell

New Strategies for Redox Catalysis

Amanda Dombrowski AbbVie

Enabling and Accelerating Drug Discovery with High Throughput Chemistry

Victoria Hélan AstraZeneca

Towards Picomole Library Synthesis and Analysis using Acoustic Technologies

Kohki Nakafuku Janssen

Discovery of Small Molecule Inhibitors Using a Modern Screening Paradigm and High Throughput Chemistry

Antivirals and Pandemic Diseases, Past, Present and Future

Program Chair: John McCauley, Merck

Jamie Tuttle Pfizer

Discovery and Development of Nirmatrelvir

Patrick Fier Merck

Developing Large-Scale Syntheses of Molnupiravir, an Antiviral for COVID-19

Phil Sanderson NIH

The Antiviral Program for Pandemics at NCATS-NIH

Uwe Schoenbeck Pfizer Inc.

Expanding the potential of RNA beyond Covid-19

Tuesday, January 31st 2023

SynthChemBio

Program Chair: Niyi Fadeyi, InduPro

Christopher am Ende Pfizer Inc.

Advancing Chemical Biology through Innovative Synthesis

Emma Grant GlaxoSmithKline

Reactive Fragments in Covalent Drug Discovery

Rob Oslund InduPro Therapeutics

Redox Activation Strategies to Profile Biological Systems

Francisco Garcia Novartis Institutes for Biomedical Research

Enhancing the Scope of Ligandability with Diverse Electrophiles

General Session: Synthesis and Med Chem

Program Chair: Amy Dounay, Colorado College

Networking Session

POSTER SESSION

Wednesday, February 1st 2023

Beyond Ro5 and Novel Modalities

Program Chair: Lou Chupak, Bristol Myers Squibb

Dave Degoey AbbVie

Discovery of bRo5 Drugs:  Lessons from the Past and Progress toward Better Prediction of Oral Absorption

Yanke Liang C4 Therapeutics

The Discovery and Characterization of CFT-18442: A Potent, Selective, and Orally Bioavailable Degrader of BRAF V600E

Geoffray Leriche Plexium

Rational Discovery of BRD4 Monovalent Protein-Degraders

Patrizio Mattei F. Hoffmann-La Roche Ltd

Discovery of RG6006, a Tethered Macrocyclic Peptide Targeting Acinetobacter baumannii

John O. Link Gilead Sciences

The Discovery and Development of Lenacapavir (GS-6207): a Twice-Yearly Injectable or Orally Dosed First-in-Class HIV Capsid Inhibitor

MacMillan Alumni Session: Topics in Medicinal and Synthetic Chemistry

Program Chair: Mike VanHyest, GSK

Raphaelle Berger Merck

Discovery of MK-6158 an oral, once daily, Soluble Guanylate Cyclase (sGC) Stimulator for the treatment of Pulmonary Arterial Hypertension

Andrew Capacci Biogen

Discovery of Selective, CNS-Penetrant Covalent Inhibitors of Bruton’s Tyrosine Kinase for the Treatment of Multiple Sclerosis

Vy Dong UCI

Choose Your Own Adventure in Metal-Hydride Catalysis

Robert M. Williams' Memorial KEYNOTE LECTURE

Program Chair: Mike VanHeyest, GSK

2021 Nobel Laureate David W.C. MacMillan Princeton University

The Development of Asymmetric Organocatalysis and Metallaphotoredox

Networking Session

Robert M. Williams' Memorial RECEPTION

Thursday, February 2nd 2023

Late Breaking Stories and 1st Disclosures

Program Chair: Dr Rebecca Gallego, Pfizer

Rob Kania Kinnate

The Discovery of KIN-2787, A Solution to the Challenges of Pan-RAF Kinase Inhibition

Manuel de Lera Ruiz Merck

Potent Dual Plasmepsin IX/X Inhibitors towards the Treatment of Malaria

Nicolas Soldermann Novartis

Conquest of a PPI Everest: Disrupting the YAP/TEAD Interface with Small Molecules

Lou Chupak Bristol Myers Squibb

Phenotypic Discovery and Optimization of Potent T-Cell Modulators: Dual Inhibition of Diacylglycerol Kinases α and ζ

Networking Session

Conference Dinner - Top of the Gondola

Media Sponsors

Bronze sponsors